Preclinical optimization of a novel combination approach exploiting a therapy-induced vulnerability to reactive oxygen species. KU Leuven
In the current project, we wish to perform essential preclinical work with the goal to bring a new concept to a clinical readiness level. We plan to 1) optimize the novel combinatorial approach in multiple (partially) responsive pdx melanoma models, 2) to expand this concept to therapy resistant melanoma tumors by co-treatment with preclinical lipogenesis inhibitors, and 3) to generalize this concept to other tumor types.
This study ...